| 24.87 -0.27 (-1.07%) | 08-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.01 | 1-year : | 34.15 |
| Resists | First : | 27.41 | Second : | 29.23 |
| Pivot price | 25.62  |
|||
| Supports | First : | 24.45 | Second : | 20.35 |
| MAs | MA(5) : | 24.94 |
MA(20) : | 25.83 |
| MA(100) : | 24.68 |
MA(250) : | 24.45 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.3 |
D(3) : | 10 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 31.77 | Low : | 15.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARQT ] has closed above bottom band by 18.3%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.14 - 25.29 | 25.29 - 25.42 |
| Low: | 24.29 - 24.45 | 24.45 - 24.59 |
| Close: | 24.64 - 24.9 | 24.9 - 25.12 |
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Thu, 27 Aug 2026
Arcutis (NASDAQ: ARQT) insider plans $956K share sale - Stock Titan
Wed, 26 Aug 2026
5 Biotech Stocks Worth Adding to Your Portfolio Now - TradingView
Wed, 19 Aug 2026
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Thu, 06 Aug 2026
Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $36.62, Implies 35% Upside - TradingView
Thu, 06 Aug 2026
Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ARQT) 2026-08-06 - Seeking Alpha
Wed, 05 Aug 2026
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 126 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 108.7 (%) |
| Shares Short | 12,690 (K) |
| Shares Short P.Month | 14,020 (K) |
| EPS | 0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | 6.1 % |
| Operating Margin | 12.6 % |
| Return on Assets (ttm) | 5 % |
| Return on Equity (ttm) | 15.8 % |
| Qtrly Rev. Growth | 59.2 % |
| Gross Profit (p.s.) | 3.36 |
| Sales Per Share | 3.69 |
| EBITDA (p.s.) | 0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 39 (M) |
| Levered Free Cash Flow | 22 (M) |
| PE Ratio | 113.04 |
| PEG Ratio | 0 |
| Price to Book value | 14.13 |
| Price to Sales | 6.73 |
| Price to Cash Flow | 79.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|